A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer

被引：7

作者：

Puglisi, Fabio ^{[1
]}

Bisagni, Giancarlo ^{[2
]}

Ciccarese, Mariangela ^{[3
]}

Fontanella, Caterina ^{[1
]}

Gamucci, Teresa ^{[4
]}

Leo, Luigi ^{[5
]}

Molino, Annamaria ^{[6
]}

Silva, Rosa Rita ^{[7
]}

Marchetti, Paolo ^{[8
,9
]}

机构：

[1] Univ Udine, Dept Med & Biol Sci, Udine, Italy

[2] Azienda Osped ASMN, Dept Oncol, Oncol Unit, Ist Ricovero & Cura Carattere Sci, Reggio Emilia, Italy

[3] Vito Fazzi Hosp, Dept Med Oncol, Lecce, Italy

[4] ASL Frosinone, Med Oncol Unit, Frosinone, Italy

[5] Azienda Osped Colli, Oncol Unit, Naples, Italy

[6] Univ Verona, Verona, Italy

[7] ASUR Marche AV2 Fabriano, Med Oncol Unit, Fabriano, Italy

[8] Sapienza Univ Rome, Med Oncol, St Andrea Hosp, Rome, Italy

[9] IDI IRCCS, Rome, Italy

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 22期

关键词：

angiogenesis; bevacizumab; breast cancer; PROGRESSION-FREE SURVIVAL; PHASE-III TRIAL; CONTAINING THERAPY; OPEN-LABEL; NEOADJUVANT CHEMOTHERAPY; PLUS BEVACIZUMAB; TARGETED THERAPIES; AND/OR BEVACIZUMAB; LOCALLY RECURRENT; CLINICAL-PRACTICE;

D O I：

10.2217/fon-2016-0295

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To gain consensus on the role of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer, a panel of expert oncologists experienced in treating patients with metastatic breast cancer in Italy participated in a Delphi consensus study. The panel reached a full consensus on the efficacy of bevacizumab plus paclitaxel and the clinical meaningfulness of the progression-free survival benefit compared with paclitaxel alone, despite the lack of an overall survival effect in clinical trials. The participants agreed that real-world data support the effectiveness and well-defined safety profile of the regimen. Views on the use of bevacizumab plus paclitaxel in specific patient populations were not unanimous and clinical judgment remains important. Nevertheless, a high level of agreement was reached.

引用

页码：2589 / 2602

页数：14

共 50 条

[31] Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer
Borson, Rachel
Harker, Graydon
Reeves, James
Beck, Thaddeus
Hager, Steven
Horvath, William
Jones, Michael
Tillinghast, Guy
Arrowsmith, Edward
Harrer, Grant
Kudrik, Fred J.
Malamud, Stephen C.
Bromund, Jane
Zeigler, Haoyue
Tai, Datchen Fritz
Kornberg, Lori J.
Obasaju, Coleman
Orlando, Mauro
Yardley, Denise A.
CLINICAL BREAST CANCER, 2012, 12 (05) : 322 - 330
[32] SAFETY AND EFFICACY OF MAINTENANCE BEVACIZUMAB IN HER2-NEGATIVE METASTATIC BREAST CANCER
Russillo, M.
Metro, G.
Giannarelli, D.
Papaldo, P.
Nistico, C.
Ferretti, G.
Cuppone, F.
D'Auria, G.
Cognetti, F.
Fabi, A.
ANNALS OF ONCOLOGY, 2010, 21 : 105 - 105
[33] HER2-negative metastatic breast cancer patients receiving first-line docetaxel: Survival data and prognostic factors
Deblock, M.
Esterni, B.
Tarpin, C.
Charaffe-Jauffret, E.
Extra, J. M.
Viens, P.
Goncalves, A.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[34] Endocrine therapy or chemotherapy as first-line therapy in hormone receptorepositive HER2-negative metastatic breast cancer patients
Jacquet, E.
Lardy-Cleaud, A.
Pistilli, B.
Franck, S.
Cottu, P.
Delaloge, S.
Debled, M.
Vanlemmens, L.
Leheurteur, M.
Guizard, A. V.
Laborde, L.
Uwer, L.
Jacot, W.
Berchery, D.
Desmoulins, I.
Ferrero, J. M.
Perrocheau, G.
Courtinard, C.
Brain, E.
Chabaud, S.
Robain, M.
Bachelot, T.
EUROPEAN JOURNAL OF CANCER, 2018, 95 : 93 - 101
[35] Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
Vrdoljak, E.
Marschner, N.
Zielinski, C.
Gligorov, J.
Cortes, J.
Puglisi, F.
Aapro, M.
Fallowfield, L.
Fontana, A.
Inbar, M.
Kahan, Z.
Welt, A.
Levy, C.
Brain, E.
Pivot, X.
Putzu, C.
Gonzalez Martin, A.
de Ducla, S.
Easton, V.
von Minckwitz, G.
ANNALS OF ONCOLOGY, 2016, 27 (11) : 2046 - 2052
[36] Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial
Gligorov, Joseph
Doval, Dinesh
Bines, Jose
Alba, Emilio
Cortes, Paulo
Pierga, Jean-Yves
Gupta, Vineet
Costa, Romulo
Srock, Stefanie
de Ducla, Sabine
Freudensprung, Ulrich
Mustacchi, Giorgio
LANCET ONCOLOGY, 2014, 15 (12): : 1351 - 1360
[37] Bevacizumab in the treatment of HER2-negative breast cancer
Lorusso, Vito
BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04): : 813 - 821
[38] Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Lobo, Christopher
Lopes, Gilberto
Baez, Odalys
Castrellon, Aurelio
Ferrell, Annapoorna
Higgins, Connie
Hurley, Erin
Hurley, Judith
Reis, Isildinha
Richman, Stephen
Seo, Pearl
Silva, Orlando
Slingerland, Joyce
Tukia, Keleni
Welsh, Catherine
Glueck, Stefan
BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (02) : 427 - 435
[39] Pooled-analysis of prospective observational studies evaluated the effectiveness and safety of bevacizumab and paclitaxel as the first-line chemotherapy for HER2-negative metastatic breast cancer
Yamashiro, H.
Yamamoto, Y.
Schneeweiss, A.
Mueller, V.
Gluz, O.
Klare, P.
Aktas, B.
Magdolna, D.
Buedi, L.
Piko, B.
Mangel, L.
Toi, M.
Morita, S.
Ohno, S.
ANNALS OF ONCOLOGY, 2020, 31 : S367 - S367
[40] Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)
Miles, D. W.
De Haas, S. L.
Romieu, G.
Chan, A.
Dirix, L.
Cortess, J.
Delmar, P. R.
Scherer, S. J.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S176 - S176

← 1 2 3 4 5 →